Protein C News and Research

RSS

Proteomics technology shows how exercise improves the efficiency of muscle energy production

Mitochondria are the cell's power plants and produce the majority of a cell's energy needs through an electrochemical process called electron transport chain coupled to another process known as oxidative phosphorylation.

27 May 2021

Study details challenges and progress toward creating a COVID-19 drug

The COVID-19 pandemic has seen scientists perform incredible feats in a short amount of time, from developing tests to new types of vaccines.

26 May 2021

Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro

Researchers from the US and Australia recently conducted some studies to assess the in vitro antiviral and virucidal (irreversible) activity of astodrimer sodium against SARS-CoV-2.

26 May 2021

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

A study conducted by researchers in the United States has shown that among twenty patients with breakthrough infection following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – all of the infections were caused by variants of concerns.

26 May 2021

Researchers identify structure of agent that causes Alzheimer's and Parkinson's diseases

Alzheimer's disease - also called dementia - where memory and cognitive functions gradually decline due to deformation and death of neurons, and Parkinson's disease that causes tremors in hands and arms impeding normal movement are major neurodegenerative diseases.

26 May 2021

New COVID-19 test can deliver highly accurate results in less than 15 minutes

A new rapid coronavirus test developed by KAUST scientists can deliver highly accurate results in less than 15 minutes.

26 May 2021

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.

26 May 2021

Could GRP78 be a therapeutic target against COVID-19?

A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.

26 May 2021

New SARS-CoV-2 variants emerge among children in United States, suggests study

As the coronavirus disease 2019 (COVID-19) pandemic approaches its eighteenth month, new variants of concern (VOCs) of the causative pathogen – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – continue to emerge all over the world. A new study explores the emergence of such VOCs among young children, below 12 years of age, and the potential consequences of this phenomenon.

26 May 2021

Tissue-resident memory T cells found in lungs of people who had COVID-19 10 months ago

In recent research by Judith Grau-Expósito et al., scientists identify circulating virus-specific T cell responses during acute SARS-CoV-2 infection with functional, migratory, and apoptotic patterns modulated by viral proteins and associated with clinical outcome.

26 May 2021

Researchers to conduct Phase 1 gene therapy trial to treat Alzheimer's disease

The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a $5 million grant to researchers at University of California San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.

26 May 2021

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Recent COVID-19 investigations have found that up to half of immunocompromised individuals struggle to produce antibodies after receiving their severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations.

26 May 2021

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

According to research from the University of California, some cases of severe coronavirus disease 2019 (COVID-19) may be related to the immunological memory of previous H3N2 influenza A infection.

26 May 2021

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

A multidisciplinary team from MassGeneral Hospital for Children (MGHfC), Brigham and Women's Hospital and other institutions have identified the mechanism of how an extremely rare but serious post-COVID-19 complication develops in children and adolescents.

26 May 2021

Scientists propose new strategies to find drugs that neutralize critical enzymes

Scientists from the University of Bath explore racemases and propose strategies for finding drugs that target these important enzymes.

26 May 2021

Moderna's COVID vaccine proves effective against South African variant in primates

Researchers in the United States have demonstrated the efficacy of Moderna’s coronavirus disease 2019 (COVID-19) vaccine at protecting against the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in non-human primates.

26 May 2021

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events.

25 May 2021

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world.

25 May 2021

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

A research group from Osaka University led by Professor Hisashi Arase and consisting of researchers from the Research Institute for Microbial Diseases, the Institute for Protein Research, the Immunology Frontier Research Center, the Center for Infectious Diseases, and the Graduate School of Medicine has discovered for the first time that both neutralizing antibodies that protect against infection as well as infection-enhancing antibodies that increase infectivity are produced after infection with SARS-CoV-2 by analyzing antibodies derived from COVID-19 patients.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

Protein C News and Research

Proteomics technology shows how exercise improves the efficiency of muscle energy production

Study details challenges and progress toward creating a COVID-19 drug

Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

Researchers identify structure of agent that causes Alzheimer's and Parkinson's diseases

New COVID-19 test can deliver highly accurate results in less than 15 minutes

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

Could GRP78 be a therapeutic target against COVID-19?

New SARS-CoV-2 variants emerge among children in United States, suggests study

Tissue-resident memory T cells found in lungs of people who had COVID-19 10 months ago

Researchers to conduct Phase 1 gene therapy trial to treat Alzheimer's disease

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Previous H3N2 influenza A infection may explain some cases of severe COVID-19

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

Scientists propose new strategies to find drugs that neutralize critical enzymes

Moderna's COVID vaccine proves effective against South African variant in primates

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News